Literature DB >> 1345817

Effect of small doses of somatostatin analog, octreotide, on gallbladder contractility in normal Chinese adults.

X F Zhu1, Y F Shi, J X Zhang, A G Harris.   

Abstract

The acute effects of single different doses of the somatostatin analog octreotide on the contractility of the gallbladder stimulated by fatty meal were studied in six healthy Chinese volunteers. Gallbladder contraction after a fatty meal was significantly suppressed by octreotide at doses of 50, 25, 12.5, and 5 micrograms. Mean duration of suppression lasted for more than 10 hr at doses of 25 and 50 micrograms, after which the gallbladder contractility was restored at 24 hr in three and four, respectively, of the six subjects. The percentage of relative gallbladder contraction (PRGC) in all subjects receiving 12.5 and 5 micrograms octreotide returned to pretreatment values at 10 hr but had not returned to normal 6 hr after the injection of 5 micrograms octreotide. In summary, octreotide inhibits the contraction of the gallbladder even with a dose as low as 5 micrograms. It appears that it may not be possible to avoid gallbladder dysfunction during long-term octreotide therapy by decreasing the dose. Further studies including modalities to increase the contractility of the gallbladder are recommended.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1345817     DOI: 10.1007/bf01308351

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  11 in total

1.  Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. French SMS 201-995 approximately equal to Acromegaly Study Group.

Authors:  G Sassolas; A G Harris; A James-Deidier
Journal:  J Clin Endocrinol Metab       Date:  1990-08       Impact factor: 5.958

2.  SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action.

Authors:  W Bauer; U Briner; W Doepfner; R Haller; R Huguenin; P Marbach; T J Petcher
Journal:  Life Sci       Date:  1982-09-13       Impact factor: 5.037

3.  Specific somatostatin-binding to cytosol of bovine gallbladder mucosa.

Authors:  E Arilla; B Colás; J C Prieto
Journal:  Biosci Rep       Date:  1986-03       Impact factor: 3.840

4.  Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety.

Authors:  K Y Ho; A J Weissberger; P Marbach; L Lazarus
Journal:  Ann Intern Med       Date:  1990-02-01       Impact factor: 25.391

5.  A critical evaluation of real-time ultrasonography for the study of gallbladder volume and contraction.

Authors:  G T Everson; D Z Braverman; M L Johnson; F Kern
Journal:  Gastroenterology       Date:  1980-07       Impact factor: 22.682

6.  Clinical and biochemical effects of incremental doses of the long-acting somatostatin analogue SMS 201-995 in ten acromegalic patients.

Authors:  Y F Shi; A G Harris; X F Zhu; J Y Deng
Journal:  Clin Endocrinol (Oxf)       Date:  1990-06       Impact factor: 3.478

Review 7.  NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut.

Authors:  P Gorden; R J Comi; P N Maton; V L Go
Journal:  Ann Intern Med       Date:  1989-01-01       Impact factor: 25.391

8.  Effect of the somatostatin analogue sandostatin (SMS 201-995) on gastrointestinal, pancreatic and biliary function and hormone release in normal men.

Authors:  B Lembcke; W Creutzfeldt; S Schleser; R Ebert; C Shaw; I Koop
Journal:  Digestion       Date:  1987       Impact factor: 3.216

9.  Effects of somatostatin on gallbladder emptying.

Authors:  R S Fisher; E Rock; G Levin; L Malmud
Journal:  Gastroenterology       Date:  1987-04       Impact factor: 22.682

10.  Postprandial gallbladder motility during long term treatment with the long-acting somatostatin analog SMS 201-995 in acromegaly.

Authors:  P A van Liessum; W P Hopman; G F Pieters; J B Jansen; A G Smals; G Rosenbusch; P W Kloppenborg; C B Lamers
Journal:  J Clin Endocrinol Metab       Date:  1989-09       Impact factor: 5.958

View more
  4 in total

Review 1.  Controversies concerning pathophysiology and management of acalculous biliary-type abdominal pain.

Authors:  Amit Rastogi; Adam Slivka; Arthur James Moser; Arnold Wald
Journal:  Dig Dis Sci       Date:  2005-08       Impact factor: 3.199

2.  Roles of gall bladder emptying and intestinal transit in the pathogenesis of octreotide induced gall bladder stones.

Authors:  S H Hussaini; S P Pereira; M J Veysey; C Kennedy; P Jenkins; G M Murphy; J A Wass; R H Dowling
Journal:  Gut       Date:  1996-05       Impact factor: 23.059

3.  Effect of octreotide on gall stone prevalence and gall bladder motility in acromegaly.

Authors:  S M Catnach; J V Anderson; P D Fairclough; R C Trembath; P A Wilson; E Parker; G M Besser; J A Wass
Journal:  Gut       Date:  1993-02       Impact factor: 23.059

4.  Effects of octreotide on biliary lipid composition and occurrence of cholesterol crystals in patients with acromegaly. A prospective study.

Authors:  S Erlinger; P Chanson; M Dumont; P Ponsot; A Warnet; A G Harris
Journal:  Dig Dis Sci       Date:  1994-11       Impact factor: 3.199

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.